Notably, Mohamed et al. [13] demonstrated that three-month LF administrations in AD patients decreased the levels of acetylcholine, serotonin, antioxidant and anti-inflammatory markers, and β-amyloid 1–42, suggesting LF’s role in AD prevention through the modulation of the phosphorylated protein kinase B/phosphatase and tensin homolog pathway. This evidence concerns the gene PTEN and Alzheimer disease.